Immuno-Biological Laboratories , Ltd. EBIT

The latest EBIT for 4570.T is $350M as of June 2026. That compares with $210M in the prior-year period — up 64.4% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Immuno-Biological Laboratories , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 4570.T's EBIT moved from $210M to $350M — a 64.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Immuno-Biological Laboratories , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 4570.T currently prints $350M for EBIT, while the sector average sits near $110B. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at Immuno-Biological Laboratories , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $350M for 4570.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting 4570.T's EBIT ($350M), review year-over-year change from $210M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.